Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.58
0.183.33%
Pre-Market: 4:54 PM EDT
Comments
Loading...
Cara Therapeutics Analyst Ratings and Price Targets | NASDAQ:CARA | Benzinga
Cara Therapeutics Inc has a consensus price target of $11.33 based on the ratings of 8 analysts. The high is $28 issued by Stifel on June 27, 2023. The low is $1 issued by Canaccord Genuity on June 13, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Needham, and HC Wainwright & Co. on June 13, 2024, May 23, 2024, and May 15, 2024, respectively. With an average price target of $3.2 between Canaccord Genuity, Needham, and HC Wainwright & Co., there's an implied -42.65% downside for Cara Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Piper Sandler
Stifel
Jefferies
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Cara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/13/2024 | Buy Now | -82.08% | Canaccord Genuity | Sumant Kulkarni44% | $120 → $12 | Downgrade | Buy → Hold | Get Alert |
| 06/13/2024 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/13/2024 | Buy Now | — | Needham | Joseph Stringer52% | — | Downgrade | Buy → Hold | Get Alert |
| 05/23/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | -35.48% | HC Wainwright & Co. | Oren Livnat61% | $43.2 → $43.2 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 79.21% | Canaccord Genuity | Sumant Kulkarni44% | $132 → $120 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2024 | Buy Now | -10.39% | Needham | Joseph Stringer52% | $72 → $60 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | -55.2% | HC Wainwright & Co. | Oren Livnat61% | $84 → $30 | Maintains | Buy | Get Alert |
| 12/18/2023 | Buy Now | 7.53% | Needham | Joseph Stringer52% | $264 → $72 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | -82.08% | Piper Sandler | David Amsellem70% | $144 → $12 | Downgrade | Overweight → Neutral | Get Alert |
| 10/19/2023 | Buy Now | 25.45% | HC Wainwright & Co. | Oren Livnat61% | $180 → $84 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 115.06% | Piper Sandler | David Amsellem70% | $156 → $144 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 294.27% | Needham | Joseph Stringer52% | → $264 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 401.8% | Stifel | Annabel Samimy68% | → $336 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 222.59% | Jefferies | Dennis Ding16% | → $216 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 168.82% | HC Wainwright & Co. | Oren Livnat61% | $240 → $180 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | -28.31% | B of A Securities | Jason Gerberry63% | $72 → $48 | Maintains | Underperform | Get Alert |
| 05/16/2023 | Buy Now | 294.27% | Needham | Joseph Stringer52% | → $264 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 294.27% | Needham | Joseph Stringer52% | → $264 | Reiterates | → Action List Buy | Get Alert |
| 04/04/2023 | Buy Now | 294.27% | Needham | Joseph Stringer52% | → $264 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 7.53% | B of A Securities | Jason Gerberry63% | $156 → $72 | Downgrade | Neutral → Underperform | Get Alert |
| 03/07/2023 | Buy Now | 186.74% | JP Morgan | Daniel Wolle9% | $228 → $192 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 348.04% | Canaccord Genuity | Sumant Kulkarni44% | $348 → $300 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 294.27% | Needham | Joseph Stringer52% | $312 → $264 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 132.98% | Piper Sandler | David Amsellem70% | $300 → $156 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 258.43% | HC Wainwright & Co. | Oren Livnat61% | $300 → $240 | Maintains | Buy | Get Alert |
| 02/17/2023 | Buy Now | 365.96% | Needham | Joseph Stringer52% | → $312 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | 348.04% | HC Wainwright & Co. | Oren Livnat61% | $360 → $300 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cara Therapeutics (CARA) stock?
The latest price target for Cara Therapeutics (NASDAQ:CARA) was reported by Canaccord Genuity on June 13, 2024. The analyst firm set a price target for $1.00 expecting CARA to fall to within 12 months (a possible -82.08% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cara Therapeutics (CARA)?
The latest analyst rating for Cara Therapeutics (NASDAQ:CARA) was provided by Canaccord Genuity, and Cara Therapeutics downgraded their hold rating.
When was the last upgrade for Cara Therapeutics (CARA)?
There is no last upgrade for Cara Therapeutics
When was the last downgrade for Cara Therapeutics (CARA)?
The last downgrade for Cara Therapeutics Inc happened on June 13, 2024 when Canaccord Genuity changed their price target from $10 to $1 for Cara Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Cara Therapeutics (CARA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
Is the Analyst Rating Cara Therapeutics (CARA) correct?
While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a downgraded with a price target of $10.00 to $1.00. The current price Cara Therapeutics (CARA) is trading at is $5.58, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.